Towards Healthcare
GMP Grade Cytokines Market Size Uptrend USD 2.79 Bn in 2025

GMP Grade Cytokines Market Insights 2025 Interleukins & Human Recombinant Segments Dominate

Projections indicate that, the global GMP grade cytokines market will increase from USD 2.54 billion in 2024 to USD 6.48 billion by 2034, experiencing a CAGR of 9.84% over the next 10 years. The rising prevalence of chronic disorders and the burgeoning biotechnology sector drive the global market. North America led the global market owing to the growing demand for personalized medicines and increasing investments.

  • Insight Code: 5941
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

FAQ's

The GMP grade cytokines market is projected to reach USD 6.48 billion by 2034, growing at a CAGR of 9.84% from 2025 to 2034.

North America is leading the GMP grade cytokines market due to the growing demand for personalized medicines, increasing investments, and the presence of key players.

Some key players include STEMCELL Technologies, Bio-Techne Corporation, and Sino Biologicals.

GMP refers to the quality control procedures set by regulatory agencies that control the authorization of pharmaceutical and medical products.

Immune cells, such as macrophages, dendritic cells, lymphocytes, monocytes, neutrophils, and eosinophils, release cytokines.

Personalized Medicine Coalition, Government of Canada, Food and Drug Administration, clinicaltrials.gov, GOV.UK